Urate Handling in the Human Body

Por Hyndman, David, Liu, Sha, Miner, Jeffrey N.
Publicado no Curr Rheumatol Rep (2016)

Mechanism of high affinity inhibition of the human urate transporter URAT1

Por Tan, Philip K., Ostertag, Traci M., Miner, Jeffrey N.
Publicado no Sci Rep (2016)

Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts

Por Miner Jeffrey N, Chapman Mark S, Chang Qing, Hedley David W
Publicado em 2010-09-01

Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts

Por Chang, Qing, Chapman, Mark S, Miner, Jeffrey N, Hedley, David W
Publicado em 2010

Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout

Por Tan, Philip K., Liu, Sha, Gunic, Esmir, Miner, Jeffrey N.
Publicado no Sci Rep (2017)

Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol

Por Perez-Ruiz, Fernando, Sundy, John S, Miner, Jeffrey N, Cravets, Matthew, Storgard, Chris
Publicado no Ann Rheum Dis (2016)

Coevolution of URAT1 and Uricase during Primate Evolution: Implications for Serum Urate Homeostasis and Gout

Por Tan, Philip K., Farrar, Jennifer E., Gaucher, Eric A., Miner, Jeffrey N.
Publicado no Mol Biol Evol (2016)

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects

Por Shen, Zancong, Gillen, Michael, Miner, Jeffrey N, Bucci, Gail, Wilson, David M, Hall, Jesse W
Publicado no Drug Des Devel Ther (2017)

Omega-3-carboxylic acids provide efficacious anti-inflammatory activity in models of crystal-mediated inflammation

Por Iverson, Cory, Bacong, Andrew, Liu, Sha, Baumgartner, Scott, Lundström, Torbjörn, Oscarsson, Jan, Miner, Jeffrey N.
Publicado no Sci Rep (2018)

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects

Por Hall, Jesse, Gillen, Michael, Liu, Sha, Miner, Jeffrey N, Valdez, Shakti, Shen, Zancong, Lee, Caroline
Publicado no Drug Des Devel Ther (2018)

The structural basis of androgen receptor activation: Intramolecular and intermolecular amino–carboxy interactions

Por Schaufele, Fred, Carbonell, Xavier, Guerbadot, Martin, Borngraeber, Sabine, Chapman, Mark S., Ma, Aye Aye K., Miner, Jeffrey N., Diamond, Marc I.
Publicado em 2005

Allosteric MEK1/2 Inhibitor Refametinib (BAY 86-9766) in Combination with Sorafenib Exhibits Antitumor Activity in Preclinical Murine and Rat Models of Hepatocellular Carcinoma

Por Schmieder, Roberta, Puehler, Florian, Neuhaus, Roland, Kissel, Maria, Adjei, Alex A, Miner, Jeffrey N, Mumberg, Dominik, Ziegelbauer, Karl, Scholz, Arne
Publicado em 2013

Xanthine oxidoreductase regulates macrophage IL1β secretion upon NLRP3 inflammasome activation

Por Ives, Annette, Nomura, Johji, Martinon, Fabio, Roger, Thierry, LeRoy, Didier, Miner, Jeffrey N., Simon, Gregoire, Busso, Nathalie, So, Alexander
Publicado no Nat Commun (2015)

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study

Por Fleischmann, Roy, Winkle, Peter, Miner, Jeffrey N, Yan, Xiaohong, Hicks, Liz, Valdez, Shakti, Hall, Jesse, Liu, Sha, Shen, Zancong, Gillen, Michael, Hernandez-Illas, Martha
Publicado no RMD Open (2018)

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study

Por Fleischmann, Roy, Winkle, Peter, Hall, Jesse, Valdez, Shakti, Liu, Sha, Yan, Xiaohong, Hicks, Liz, Lee, Caroline, Miner, Jeffrey N, Gillen, Michael, Hernandez-Illas, Martha
Publicado no RMD Open (2018)

Structure of the ligand-binding domain (LBD) of human androgen receptor in complex with a selective modulator LGD2226

Por Wang, Feng, Liu, Xiao-qin, Li, He, Liang, Kai-ni, Miner, Jeffrey N., Hong, Mei, Kallel, E. Adam, van Oeveren, Arjan, Zhi, Lin, Jiang, Tao
Publicado em 2006

Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout

Por Kankam, Martin, Hall, Jesse, Gillen, Michael, Yang, Xiaojuan, Shen, Zancong, Lee, Caroline, Liu, Sha, Miner, Jeffrey N., Walker, Susan, Clauson, Vicki, Wilson, David, Nguyen, Mai
Publicado no J Clin Pharmacol (2018)

Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein–protein interaction profile

Por Miner, Jeffrey N., Ardecky, Bob, Benbatoul, Khalid, Griffiths, Kimberly, Larson, Christopher J., Mais, Dale E., Marschke, Keith, Rosen, Jon, Vajda, Eric, Zhi, Lin, Negro-Vilar, Andres
Publicado em 2007

Accuracy of the HumaSens(plus) point-of-care uric acid meter using capillary blood obtained by fingertip puncture

Por Fabre, Stéphanie, Clerson, Pierre, Launay, Jean-Marie, Gautier, Jean-François, Vidal-Trecan, Tiphaine, Riveline, Jean-Pierre, Platt, Adam, Abrahamsson, Anna, Miner, Jeffrey N., Hughes, Glen, Richette, Pascal, Bardin, Thomas
Publicado no Arthritis Res Ther (2018)

Erratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney

Por Miner, Jeffrey N., Tan, Philip K., Hyndman, David, Liu, Sha, Iverson, Cory, Nanavati, Payal, Hagerty, David T., Manhard, Kimberly, Shen, Zancong, Girardet, Jean-Luc, Yeh, Li-Tain, Terkeltaub, Robert, Quart, Barry
Publicado no Arthritis Res Ther (2016)